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The effects of Nef molecules on immature dendritic cells (iDCs) were analyzed using recombinant human immunodeficiency virus type 1
(HIV-1) with intact nef gene, pseudotyped with vesicular stomatitis virus glycoprotein, HIV/VSV-G/+Nef. When iDCs were infected with
HIV/VSV-G/+Nef, the surface expression of CD1a, a molecule for presenting glycolipid/lipid antigens, was selectively down-regulated
among CD1 molecules (CD1a, -b, -c, and -d) as well as class I MHC. Moreover, the CD1a molecules were also down-modulated and co-
localized with DsRed2-tagged-Nef in CD1a-transfected cells. Their co-localization was dependent upon CD1a cytoplasmic tail and the CD1a
was redistributed from cell surface to LAMP-1+ late endosomal/lysosomal compartment. These findings reveal that the HIV-1-Nef interferes
with the intracellular trafficking of CD1a, and suggest the involvement of CD1a-restricted immune effectors in the protective immunity
against HIV-1 infection, which implicates the feasibility of virus-derived glycolipid/lipid antigens together with epitope peptides for the
vaccine development.
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The Nef protein is a key factor for the progression of
human immunodeficiency virus type-1 (HIV-1) infection.
Nef-deficient HIV-1 as well as simian immunodeficiency
virus (SIV) markedly slowed clinical manifestation of AIDS
(Cullen, 1998). Transgenic mice expressing the nef gene
developed an AIDS-like disease (Hanna et al., 1998). Thus,
the Nef appears to be strongly associated with induction and
progression of immunodeficient state.
Indeed, a critical role of Nef in supporting virus infection
and replication has been noted in CD4-positive T cells and
dendritic cells (DCs) (Chowers et al., 1994; de Ronde et al.,
1992) and several pathways that Nef mediates to disrupt
host defense have also been suggested (Fackler and Baur,0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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expression of nef down-regulated the surface expression of
HLA-A and -B but not HLA-C to avoid immune recognition
by both cytotoxic T lymphocytes (CTLs) and NK cells
(Cohen et al., 1999; Le Gall et al., 1998). Moreover, it has
recently been shown that HIV-1 Nef inhibits class II MHC
molecule-restricted peptide presentation to specific T cells
by reducing the surface level of peptide-loaded class II
MHC whereas increasing the levels of immature class II
molecules occupied with the invariant chain (Stumptner-
Cuvelette et al., 2001). Therefore, both class I and class II
MHC molecule-dependent activation of peptide-specific
effector T cells appear to be impaired in the presence of
Nef. However, the exact mechanism of enhanced virus
replication mediated through Nef has not been fully under-
stood yet.
Besides class I and II MHC, a family of CD1 (CD1a, -b,
-c, and -d), a third lineage of antigen-presenting molecules,
has recently been identified (Porcelli et al., 1998). Unlike
those MHC molecules that bind peptide antigens, CD1
molecules bind lipid or glycolipid antigens and present them
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cells, and thus mediated distinct but complementary path-
ways for controlling pathogens. For example, CD1a, -b, and
-c molecules could present glycolipid antigens derived from
Mycobacterium tuberculosis and M. leprae, which have the
capacity to replicate only inside of the infected cells
(Porcelli and Modlin, 1999). Moreover, CD1d molecules
are known to present a unique glycolipid antigen, a-galac-
tosyl ceramide, to NKT cells (Kawano et al., 1997). Those
CD1 molecules are predominantly expressed on DCs, a
primary target for HIV-1 infection (Messmer et al., 2000;
Spira et al., 1996).
On the other hand, it has recently been demonstrated that
some lipids such as ganglioside (GM1) (Zheng et al., 2001)
and cholesterol (Guyader et al., 2002; Viard et al., 2002) in
HIV-1 virions were essential for viral infectivity and HIV-1
became more infectious when it budded from lipid rafts of
host cellular membrane, where Nef seemed to play a major
role (Zheng et al., 2001). Furthermore, it has been reported
that HIV-1 infection altered the cellular lipid metabolism,
which was characterized by a shift in phospholipid synthesis
to neutral lipid synthesis (Raulin, 2002) and HIV-1 Nef
increases the synthesis of and transports cholesterol to lipid
rafts to provide essential building block for the formation of
virions (Zheng et al., 2003). Moreover, they showed that
mutant Nef protein dramatically reduced viral infectivity,
suggesting synthesis of virus-specific lipid associated with
virus infectivity might be affected by Nef. If such intracel-
lularly synthesized virus-associated lipid would be a target
for immune surveillance system to control HIV-1, HIV-1
Nef might also interfere with the presentation of CD1-
restricted glycolipid/lipid antigens via down-modulation of
the surface expression of those CD1s on dendritic cells in a
similar manner observed in class I MHC molecules on T
lymphocytes (Collins et al., 1998).
In the present study, by comparing with the down-
modulation of class I MHC molecules in immature den-
dritic cells (iDCs) having strong antigen processing capac-
ity, we analyzed the effects of HIV-1 Nef on the expression
of CD1s, particularly on CD1a, a most prominent CD1
isoform expressing on epidermal Langerhans cells (Caux et
al., 1992) and iDCs. However, those DCs will not divide
readily in general and difficult to be infected with retro-
viral vectors. For this purpose, we have developed recom-
binant HIV-1 particles either with or without the nef gene
pseudotyped with vesicular stomatitis virus glycoprotein
(VSV-G), carrying enhanced green fluorescent protein
(EGFP) gene in place of the env to identify the infected
cells (Shinya et al., 2003). Those VSV-G pseudotyped
virions, either bearing nef gene or not, showed strong
capacity to infect both dividing and non-dividing cells like
DCs.
Here, we show that the surface expression of CD1a
molecules was significantly down-modulated as well as
class I MHC when iDCs were infected with those pseudo-
typed virions expressing the intact nef gene. In addition,using the Nef-DsRed2 fusion gene encoding Nef molecule
tagged with DsRed2, we demonstrate that the CD1a mole-
cules were co-localized with Nef, and that those CD1a and
Nef were redistributed from the cell surface to LAMP-1
positive late endosomal/lysosomal compartments.Results
Infection of PBMC-derived iDCs with recombinant HIV-1
virions pseudotyped with VSV-G
Before examining the effect of Nef protein on CD1
molecules, we confirmed the expression of HIV-1 Nef in
DCs derived from peripheral blood mononuclear cells
(PBMC) infected with VSV-G pseudotyped HIV-1 virions
having nef gene (HIV/VSV-G/+Nef) (Fig. 1B, lane 1), but
not in those infected with nef disrupted HIV/VSV-G/Nef
(Fig. 1B, lane 2) by Western blot analysis. The PBMC-
derived DCs showed typical surface phenotype of iDCs
such as CD1a and HLA-DR but did not express the
maturation marker, CD83, and they became matured DCs
expressing the CD83 with up-regulation of CD80, CD86,
and HLA-DR when they were incubated with 10 ng/ml of
LPS for 2 days (data not shown). Quantitative flow cyto-
metric analysis revealed that the cells were efficiently
infected with pseudotyped virions and there was no signif-
icant difference in the percentage of EGFP-positive cells
and in the EGFP intensity between HIV/VSV-G/+Nef and
HIV/VSV-G/Nef (data not shown).
HIV-1 Nef-induced class I MHC down-regulation in iDCs
Based on these observations, we examined the surface
expression of class I MHC molecules among the EGFP-
positive iDCs. Contrary to the previous report using adeno-
viral vector to transfer nef gene (Messmer et al., 2002),
down-regulation of the surface expression of class I MHC
on iDCs by HIV-1 Nef was observed using anti-HLA-abc
antibody but not prominent (Fig. 1C). Thus, to observe the
effect of Nef on the class I expression more clearly, we next
focused on analyzing the particular type of HLA-a mole-
cules such as HLA-A2. The significant down-regulation of
HLA-A2 by HIV-1 Nef on the iDCs from two distinct
donors with HLA-A2 was observed (Fig. 1D).
Selective down-regulation of CD1a by HIV-1 Nef in iDCs
Furthermore, as shown in Fig. 2, we examined the effect
of HIV-1 Nef on CD1 expression in iDCs based on the
structural similarity between class I MHC and CD1 mole-
cules, both of which have 2-microglobulin. We did observe
that the surface expression of CD1a molecules was selec-
tively down-regulated among CD1s (CD1a, CD1b, CD1c,
and CD1d) in those iDCs infected with HIV/VSV-G/+Nef in
comparison with the iDCs infected with the Nef-defective
Fig. 1. (A) DNA construct of the recombinant HIV-1 in which a part of env gene is replaced with enhanced green fluorescent protein (EGFP) gene. A frame
shift was inserted in the XhoI recognition site in nef gene (pES8). To generate recombinant HIV-1 particles, HCT116 cells were transfected with VSV-G
expression plasmid (pMDG) and either pES7 or pES8. (B) Western blotting analysis for Nef protein in PBMC-DCs. An equal number (3  106) of PBMC-DCs
were infected with the recombinant HIV-1 derived from pES7 plus pMDG (HIV/VSV-G/+Nef) or that from pES8 plus pMDG (HIV/VSV-G/-Nef). Three days
after the infection, cells were lysed and the proteins were resolved on a 4–12% NuPAGE Bis–Tris gel (Invitrogen) followed by immunodetection of Nef
protein with the rabbit anti-Nef serum. (C and D) Nef down-regulates class I MHC surface expression in iDCs. Immature DCs were prepared from the donors
with HLA-A2 and infected with HIV/VSV-G/+Nef (+Nef) or HIV/VSV-G/Nef (Nef). After 3–4 days, the cells were incubated with anti-HLA-abc (C) or
-HLA-A2 Ab (D), and subsequently stained with anti-mouse IgG polyclonal antibody conjugated with PE and analyzed with FACS. Gated EGFP-positive DCs
were shown in the histograms in right panels. Mean fluorescence intensity (MFI) was also shown. Data shown are the representative of three independent
experiments.
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significant (n = 7; *P < 0.05) (Fig. 2B). As far as we have
observed carefully, we could not see any down-modulation
on the surface expression of CD1d. It should be noted that
the expression of CD83, CD86, and HLA-DR, common
maturation markers of DCs, has not been altered between
the cells infected with HIV/VSV-G/+Nef or those with HIV/
VSV-G/Nef (Fig. 2C), suggesting that HIV-1 Nef has no
effects on the maturation of iDCs.Selective down-regulation of CD1a in stably transfected
JY cells
To confirm the selective down-regulation of CD1a ex-
pression among group I CD1 molecules, JY cells were
stably transfected with either CD1a, CD1b, or CD1c gene,
further infected with HIV/VSV-G/+Nef or HIV/VSV-G/-Nef
and the surface expression of those molecules was analyzed
by FACS. Similar to the case of iDCs, HIV-1 Nef selectively
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Fig. 3. Nef selectively down-regulates CD1a surface expression in JY. JY cells stably transfected with either CD1a-, CD1b-, or CD1c gene were infected with
HIV/VSV-G/+Nef (+Nef) or HIV/VSV-G/Nef (Nef). After 3–4 days, the cells were incubated with anti-CD1a Ab, -CD1b Ab, or -CD1c Ab, respectively,
and subsequently stained with anti-mouse IgG polyclonal antibody conjugated with PE and analyzed by flow cytometry. The GFP-positive cells were gated and
the histograms for CD1a, CD1b, or CD1c surface expression were shown. Shaded histogram indicates the cells infected with HIV/VSV-G/+Nef and solid line
indicates those infected with HIV/VSV-G/Nef. Data shown are the representative of three independent experiments.
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molecules on JY cells (Fig. 3). Therefore, as had been
observed between HIV-1 Nef and class I MHC molecules
(Doms and Trono, 2000), the molecular interaction between
CD1a and HIV-1 nef gene product was indicated in the HIV-
1-infected CD1a-expressing cells.
DsRed2-tagged Nef protein co-localized with CD1a
To further investigate the interaction between CD1a and
HIV-1 Nef, we designed an expression plasmid of Nef-
DsRed2 chimeric gene (pNef-DsRed2) (Fig. 4A) by insert-
ing the HIV-1 nef gene derived from pNL4-3 to the N-
terminal end of DsRed2 in pDsRed2-N1 (Clontech, Palo
Alto, CA). The expression of the Nef-DsRed2 fusion protein
in HCT116 cells was confirmed by immunoblotting analysis
using rabbit anti-Nef serum (data not shown). Then, the
CD1a-positive HCT116 cells were further transfected with
pNef-DsRed2 or control pDsRed2-N1. After 72 h of incu-
bation, the surface expression of CD1a and DsRed2 was
analyzed by FACS. The surface intensity of the CD1a of
DsRed2-positive cells transfected with pNef-DsRed2 was
down-regulated in proportion to that of Nef-DsRed2 (Fig.
4B), which was statistically significant in comparison with
those transfected with Nef-negative pDsRed2-N1 (n = 6;
**P < 0.01) (Fig. 4C).
Next, using confocal laser microscopy and HeLa cells,
we determined the subcellular localization of Nef and CD1a
molecules when they were expressed in the same cells
simultaneously. As a control, HeLa cells were transfected
with CD1a gene alone, and the CD1a molecules were
predominantly localized on the cell surface (Fig. 5A-1).
When HeLa cells were transfected with an expression vectorFig. 2. HIV-1 Nef selectively down-regulates CD1a surface expression without m
panels) or HIV/VSV-G/Nef (Nef, middle panels). After 3–4 days, the cells
subsequently stained with anti-mouse IgG polyclonal antibody conjugated with PE
experiment of at least three similar experiments (different donors). (B) Mean flu
donors (+Nef vs. Nef, *P < 0.05). (C) The infected iDCs were also stained with P
gated and histograms for CD83, CD86, and HLA-DR surface expression were show
solid line indicates those infected with HIV/VSV-G/Nef.for CD1a together with control DsRed2 plasmid, the CD1a
molecules remained on the cell surface (green, Figs. 5A-2
and -4), indicating that the Nef-negative DsRed2 (red, Figs.
5A-3 and -4) did not affect the subcellular localization of
CD1a at all. In contrast, when HeLa cells were transfected
with the CD1a gene and the DsRed2-tagged Nef gene,
subcellular localization of CD1a (green, Fig. 5A-5) was
significantly different from that of CD1a alone (Figs. 5A-1
and -2) and indeed those two molecules, CD1a and DsRed2-
tagged Nef (red, Fig. 5A-6), were co-localized (yellow, Fig.
5A-7). These results suggest that redistribution of CD1a
molecules from the cell surface to the intracellular compart-
ments was mediated by HIV-1 Nef, resulting in the down-
regulation of CD1a surface expression.
Co-localization of CD1a and Nef is dependent on the CD1a
cytoplasmic tail
To clarify the molecular basis of the down-regulation of
CD1a by Nef, we designed a mutant of CD1a gene, which
lacked C-terminal three amino acids (CFC) in the cytoplas-
mic domain (RKRCFC), termed CD1a.del(325-7) (Table 1).
As demonstrated in Fig. 5A-8, when HeLa cells were
transfected with the CD1a.del(325-7) gene, intracellular
distribution of CD1a was not significantly changed com-
pared with that of authentic CD1a (Fig. 5A-1). Moreover,
when Nef-DsRed2 and CD1a.del(325-7) were expressed in
HeLa cells simultaneously, the CD1a molecules were main-
ly localized around the cell surface (green, Figs. 5A-9 and
-11) and did not co-localize with Nef-DsRed2 at all (red,
Figs. 5A-10 and -11). Thus, the co-localization of CD1a and
Nef is associated with the C-terminal three amino acids,
CFC, within the cytoplasmic domain of CD1a.aturation in iDCs. iDCs were infected with HIV/VSV-G/+Nef (+Nef, left
were incubated with anti-CD1a, -CD1b, -CD1c, or -CD1d antibodies and
and analyzed with flow cytometry. Data are shown from one representative
orescence intensity (MFI) of the GFP-gated DCs was calculated for seven
E-conjugated anti-CD83, -CD86, or -HLA-DR. The GFP-positive cells were
n. Shaded histogram indicates the cells infected with HIV/VSV-G/+Nef and
Fig. 4. CD1a expression was down-regulated by DsRed2-tagged Nef. (A)
Nef gene was cloned from pNL4-3 and inserted in the multiple cloning sites
of pDsRed2-N1 (Clontech) in frame for Nef-DsRed2 fusion protein
production. (B) HCT116 cells were stably transfected with a CD1a gene,
and subsequently transfected with either an expression plasmid of Nef
tagged with DsRed2 (left panel) or that of DsRed2 without Nef (right
panel), incubated for 72 h, and analyzed the expression of CD1a and
DsRed2 expression with FACS. Data are shown from one representative
experiment of six similar experiments. (C) The FITC MFI of the DsRed2-
gated cells was calculated for six experiments. (Nef-DsRed2 vs. DsRed2,
**P < 0.01).
E. Shinya et al. / Virology 326 (2004) 79–8984CD1a molecules were mainly redistributed to the late
endosomal/lysosomal compartments by HIV-1 Nef
To further determine the actual intracellular compart-
ments where the DsRed2-tagged Nef and CD1a were
expressed, their intracellular localization was compared with
that of endogenous LAMP-1 (a marker for late endosomes
and lysosomes) (Fig. 5B-1). Seventy-two hours after the
simultaneous transfection with the CD1a and Nef-DsRed2
gene (ratio 10:1), the HeLa cells were analyzed by confocal
microscopy after labeling with an antibody to LAMP-1.
DsRed2-tagged Nef (Fig. 5B-3), which was simultaneously
expressed with CD1a and supposed to be well co-localizedwith CD1a in HeLa cells, and LAMP-1 (green, Fig. 5B-2)
were superimposable (yellow, Fig. 5B-4). These results
indicate that the redistribution of CD1a molecules from
the cell surface to LAMP-1+ late endosomal/lysosomal
compartments was mediated by HIV-1 Nef, which may
account for the down-modulation of their surface expression
induced by Nef.Discussion
We demonstrated here for the first time that endogenous-
ly expressed HIV-1 nef down-modulated the surface expres-
sion of CD1a molecules on iDCs, which have been thought
as principal cells to transmit the HIV-1 virions to CD4-
positive T cells (Cameron et al., 1992; Pope et al., 1994;
Weissman et al., 1996). We have also shown that the co-
localization of CD1a and Nef depends on the C-terminal
three amino acids, CFC, within CD1a cytoplasmic tail.
The effects of Nef on the intracellular trafficking of
several proteins are variable. Class I MHC (Cohen et al.,
1999; Le Gall et al., 1998), CD4 (Aiken et al., 1994), and
CD28 (Swigut et al., 2001) molecules are down-modulated,
while surface expression of DC-SIGN, the invariant chain of
class II MHC (Stumptner-Cuvelette and Benaroch, 2002),
TNF, and LIGHT cytokines (Lama and Ware, 2000) are
enhanced by Nef. Down-regulation of surface expression of
class I MHC (Andrieu et al., 2001; Schwartz et al., 1996)
and CD4 (Aiken et al., 1994; Garcia and Miller, 1991) is
mediated by distinct mechanisms of Nef (Doms and Trono,
2000; Geyer et al., 2001). Previous results indicate that Nef-
induced endocytosis of CD4 and class I MHC requires intact
native endocytic signals in the target molecules, the di-
leucine sorting motif in the CD4 cytoplasmic domain
(Aiken et al., 1994; Hua and Cullen, 1997; Salghetti et al.,
1995), while Tyr320 in the cytoplasmic domain of HLA-A2
and B7 heavy chains (Cohen et al., 1999; Greenberg et al.,
1998; Le Gall et al., 1998). A tyrosine-based endosomal
targeting sequences (YXXZ, where Y is tyrosine, X is any
amino acid, and Z is a hydrophobic amino acid) are present
in the cytoplasmic domain of CD1 proteins other than CD1a
(Sugita et al., 1996) (Table 1), and CD1a lacks any known
endosomal targeting motif such as di-leucine motif or
tyrosine-based motif (Balk et al., 1989; Calabi and Milstein,
1986) but only six amino acids, RKRCFC, where CFC
seemed to be involved in the interaction between Nef and
CD1a. Anyway, it is to be elucidated further what kind of
mechanism would be involved in the interaction between
HIV-1 Nef and CD1a.
Giovanna Quaranta et al. (2002) have reported that CD1a
molecules on iDCs were up-regulated when recombinant
Nef protein was added to the culture. This opposite obser-
vation might come from the fact that they used recombinant
Nef protein instead of infectious virions. Externally added
proteins would generally be degraded soon after endocy-
tosed by iDCs and would not change intracellular lipid
Table 1
Amino acids sequence of the cytoplasmic domain of CD1
CD1a RKRCFC
CD1a.del(325-7) RKR
CD1b RRSYQNIP
CD1c KKHCSYQDI
CD1d SRFKRQTSYQGVL
A tyrosine-based endosomal targeting sequence is underlined.
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2002). Such changes of lipid conditions might affect the
situation of CD1a and activate the capacity for sampling
lipid/glycolipid antigens. Also, it would be impossible to
identify the cells gained the Nef protein in their case, and
consequently, they might include unaffected control cells for
their analysis. However, in our case, only nef-expressing
cells were counted via EGFP expression by FACS. More-
over, CD1a suppression in DCs by wild-type HIV-1 infec-
tion has recently been reported (Kawamura et al., 2003).
Therefore, we speculate that CD1a down-modulation in
iDCs would be induced by HIV-1 infection through inter-
nally synthesized virus-derived Nef protein and changes of
the cellular lipid conditions in HIV-1-infected cells could be
detected by specific immune effectors via CD1a antigen-
presenting molecules.As has also recently been reported, both HLA-A and
HLA-B-restricted cytotoxic T lymphocytes (CTLs) and
natural killer (NK) cells are thought to be critical for
controlling virus spread in HIV-1 infection (Goulder and
Walker, 1999). In addition to those cells, our findings
suggest the importance of CD1a molecule-restricted immune
effectors that might recognize HIV-1-derived lipid/glycolip-
id antigens for governing the fatal pathogen. Indeed, CD1a-
restricted tumor-specific T-cell responses was suggested in
human cancers very recently (Coventry and Heinzel, 2004).
Although there has not been identified any CD1a-presented
glycolipid/lipid antigens in virus-infected cells, the fact that
HIV-1 Nef increases the synthesis of virus-specific choles-
terol in the virus-infected cells (Zheng et al., 2003) indicates
that HIV-1-associated newly synthesized lipid antigens
might be presented by the CD1a molecules.
There has been tremendous efforts to develop anti-HIV
vaccines so far. However, none of them seems to be highly
effective as expected. Actually, all of such vaccines have
been based on the peptide antigens or their encoded genes.
In contrast, preinjection of rhesus macaques with nef-gene
deleted SIV (SIV-Dnef) (Connor et al., 1998; Kirchhoff et
al., 1995; Wyand et al., 1999) or SHIV (SHIV-Dnef) (Enose
et al., 2002) showed protective effects against infectious
virions. These observations suggest that Nef conceals theFig. 5. CD1a was co-localized with DsRed2-tagged Nef, and was
redistributed to LAMP-1 positive late endosomal/lysosomal domain. HeLa
cells were transfected with 5.4 Ag of CD1a plasmid (A-2–7, B-2–4)
together with 0.6 Ag of either Nef-DsRed2 fusion plasmid (A-5, -6, and -7;
B-2, -3, and -4) or 0.6 Ag of DsRed2 plasmid (A-2, -3, and -4) in 60-mm
culture dish. After 72 h of incubation, the cells were fixed and
permeabilized. CD1a was revealed by indirect immunofluorescence using
anti-CD1a antibody and FITC-conjugated second antibody. (A) CD1a was
expressed predominantly on the cell surface (green, A-1). CD1a was still at
the cells surface (green, A-2 and -4) with DsRed2 without Nef (red, A-3).
But, with DsRed2-tagged Nef (red, A-6), CD1a was distributed in the
perinuclear area (green, A-5) and they were well co-localized (yellow, A-7).
When the C-terminal three amino acids (CFC) of CD1a cytoplasmic
domain (RKRCFC) were deleted [CD1a.del(325-7)], CD1a.del(325-7) was
still distributed mainly at the cells surface (green, A-8) and stayed at the cell
surface (green, A-9 and -11) and did not co-localize with Ds-Red2-tagged
Nef (red in A-10 and -11) at all when they were produced simultaneously in
the HeLa cells. (B) A late endosomal/lysosomal marker, LAMP-1, was
stained in normal HeLa cells (B-1) and in the HeLa cells doubly transfected
with CD1a and DsRed2-tagged Nef to specify which subcellular
compartment of the cells CD1a and Nef was co-localized. DsRed2-tagged
Nef (red, B-3) and LAMP-1 (green, B-2) were significantly superimposable
(yellow, B-4), indicating that CD1a was redistributed from the cell surface
to LAMP-1 positive late endosomal/lysosomal compartment by Nef.
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nef gene will disclose such antigens to activate immune
effectors. Our current results indicate the importance of
CD1a-restricted lipid/glycolipid-specific immunity for the
protection as well as class I MHC molecule-restricted
peptide-specific immune responses against HIV-1 infection.
Thus, lipid/glycolipid-specific immunity together with pep-
tide-specific immunity might make a more potent vaccine.
The findings shown in the present study will offer another
strategy to conquer the HIV-1 infection and open a new era
for vaccine development.Materials and methods
Cells and medium
Human colon cancer-derived HCT116 cells (ATCC
CCL 247) and HeLa cells (ATCC CCL 2) were cultured
in Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 10% FCS (Moregate, Queensland, Australia),
penicillin (50 U/ml), and streptomycin (50 U/ml) (Invitro-
gen, Carlsbad, CA). JY cells (a human B lymphoblastoid
cell line) (Russell et al., 1996) stably transfected with
CD1a, CD1b, or CD1c (Sugita et al., 1999) were cultured
in RPMI 1640 (Sigma-Aldrich, St. Louis, MO)-based
complete T-cell medium (CTM) (Takahashi et al., 1996)
supplemented with 10% FCS, 2 mM L-glutamine, 100
units/ml penicillin, and 100 Ag/ml streptomycin, 20 mM
Hepes, 1mM sodium pyruvate and 55 AM 2-mercapto-
ethanol (2-ME) (all from Invitrogen) and hygromycin B
(0.2 mg/ml) (Sigma-Aldrich).
Antibodies
The mouse monoclonal antibody (mAb) 183-H12-5C
(Anti-p24) and anti-HIV human immunoglobulin (HIV-
IGTM) were obtained from the NIH AIDS Research and
Reference Reagent Program (catalogue number: 3957). The
phycoerythrin (PE)-conjugated mouse mAb HB15e (anti-
CD83) was purchased from BD Pharmingen (San Diego,
CA). PE-conjugated goat F(abV)2 antibody to mouse IgG
(IM0855) was from Beckman Coulter (Fullerton, CA). The
mouse mAb PA2.1 (anti-human HLA-A2, Aw69) was from
ATCC (HB-117). The mouse mAb 10H3 (antihuman CD1a)
(Olive et al., 1984) and rabbit polyclonal antisera against
lysosome-associated membrane protein-1 (LAMP-1) (Carls-
son et al., 1988) were also utilized.
Establishment of pseudotyped HIV virions encoding EGFP
gene
As has been reported recently (Shinya et al., 2003), the
HIV-1 env region between 6159 and 7612 of pNL4-3 (Adachi
et al., 1986) was replaced with EGFP to make pES7 plasmid
having the nef gene (Fig. 1A). Then, a frame shift mutationwas introduced in nef at the XhoI site of pES7 to construct
pES8 plasmid. HCT116 cells were doubly transfected with
VSV-G expression plasmids, pMDG (Naldini et al., 1996)
and either pES7 or pES8, for the establishment of two types
of VSV-G pseudotyped recombinant HIV-1 virions, HIV/
VSV-G/+Nef andHIV/VSV-G/Nef, respectively. Polyethy-
lenimine (PEI, 25 kDa, Sigma-Aldrich) was used for the
transfection as described previously (Zhao-Emonet et al.,
1998). Twenty-four hours later, the cells were washed with
phosphate-buffered saline (PBS) and resuspended in fresh
medium. Seventy-two hours after the transfection, the
cultured supernatant was collected, filtrated through a 0.45-
Am filter and stored frozen at 150 jC. Virus titer was
determined based on HIV-1 p24 antigen concentration in
the culture medium of the transfected HCT116 cells by
enzyme-linked immunosorbent assay (ELISA).
Measurement of p24 antigen by ELISA
Quantitative analysis of the p24 gag protein in the culture
supernatant was performed as described previously (Wehrly
and Chesebro, 1997). Briefly, Immulon II plates (Dynex
Technologies, Chantilly, VA) were coated with monoclonal
anti-HIV-1 p24 antibody (183-H12-5C) (Chesebro et al.,
1992; Toohey et al., 1995), and the samples were incubated
in the plates for 30 min. After washing, biotinylated human
anti-HIV immunoglobulin was added to detect p24. HIV-1
p25/24 Gag protein (NIH AIDS Research and Reference
Reagent Program) (Steimer et al., 1986) was used as a
standard.
Induction of iDCs from peripheral blood mononuclear cells
(PBMCs)
Immature DCs were obtained from PBMCs as described
recently (Ichikawa et al., 2003; Takeuchi et al., 2003). In
brief, PBMCs were freshly isolated with Ficoll-paque
(Amersham-Pharmacia, Uppsala, Sweden) from peripheral
blood of healthy volunteers, and CD14+ monocytes were
immediately separated by magnetic depletion using a mono-
cyte isolation kit (Miltenyi Biotec, Bergisch Gladbach,
Germany) containing hapten-conjugated antibodies to
CD3, CD7, CD19, CD45RA, CD56, and anti-IgE Abs and
a magnetic cell separator (MACS, Miltenyi Biotec) accord-
ing to the manufacturer’s instructions, routinely resulting in
>90% purity of CD14+ cells. Cells were cultured in 24-well
culture plates for 6–7 days in complete medium supple-
mented with 50 ng/ml GM-CSF (PeproTech, Rocky Hill,
NJ) and 20 ng/ml IL-4 (Biosource Intl., Camarillo, CA) to
obtain iDCs. At days 2 and 4, fresh medium supplemented
with the abovementioned cytokines was added.
Infection of iDCs with recombinant viruses
Immature DCs were distributed in the culture vessels at
1  106 cells/ml and the indicated viral stock was added to
E. Shinya et al. / Virology 326 (2004) 79–89 87each well (corresponding to 0.4 ng of p24/105 cells) in the
presence of GM-CSF and IL-4. After 3–4 days of incuba-
tion, the infected DCs were harvested and labeled with
designated antibodies for fluorescence-activated cell sorter
(FACS) analysis to examine the phenotype using FACScan
by CellQuest software (Becton and Dickinson, San Jose,
CA).
Plasmid encoding CD1a gene
Total RNA was obtained from iDCs using NucleoSpin
RNA II (Macherey-Nagel, Duren, Germany). For cloning of
the human CD1a gene, reverse transcriptase reaction with
SuperScript II reverse transcriptase (Invitrogen), and subse-
quent polymerase chain reaction (PCR) with PFU turbo
DNA polymerase (Stratagene, La Jolla, CA) and following
oligonucleotides, 5V-CGGGATCCATGCTGTTTTTGC-
TACTTCC-3V and 5V-TTACTAACAGAAACAGCG-
TTTCCTGA-3V, creating a BamHI site at the 5V end, were
performed. The amplified double-strand DNA fragment was
inserted between BamHI and PmeI site of pEF1/myc-HisC
plasmid (Invitrogen), termed CD1a/EF1. The cloned human
CD1a gene was confirmed by sequencing. Then, the 3V end
of CD1a gene encoding three amino acids at the C-terminal
of CD1a cytoplasmic domain in CD1a/EF1 were deleted by
inserting the stop codon and termed CD1a.del(325-7)/EF1,
respectively.
Plasmid encoding Nef-DsRed2 fusion gene
Nef gene was cloned from pNL4-3 genetic clone by
polymerase chain reaction (PCR), creating an EcoRI site at
the 5V end and BamHI site at the 3V end of nef using the
oligonucleotides, 5V-CCGAATTCATGGGTGGCAAG-
TGGTCA and 3V-CGGGATCCCGGCAGTTCTTGAAG-
TACTCCGG with the elimination of stop codon. The nef
gene and DsRed2 gene were fused in-frame using EcoRI
and BamHI sites, by inserting the cloned nef gene in the
multiple cloning sites of pDsRed2-N1 (Clontech), termed
pNef-DsRed2.
Immunofluorescence labeling and confocal microscopic
analysis
HeLa cells were plated at 50% confluence on day 0 in
60-mm culture dishes. On day 1, the cells were doubly
transfected with the plasmids, CD1a/EF1 and either pNef-
DsRed2 or pDsRed2-N1 using Trans-IT-HeLaMONSTER
(Mirus, WI). On day 2, the cells were trypsinized and
transferred to Lab-Tech chamber slides (Nalge Nunc,
Rochester, NY). On day 4, the cells were fixed with 2%
formaldehyde in PBS for 10 min at room temperature,
permeabilized with 0.2% saponin, and then processed for
immunofluorescence microscopy. After the permeabilized
cells were stained with mouse mAb 10H3 (anti-CD1a) and
goat FITC-conjugated donkey F(abV)2 antibody to mouseIgG (Jackson Immunoresearch Lab., West Grove, PA), the
stained cells were viewed using a Zeiss LSM510 confocal
laser scanning microscope equipped with a 100 1.30 NA
Plan-NeoFluor oil-immersion lens (Carl Zeiss, Jena, Ger-
many). Laser lines at 488 and 545 nm were used for
excitation of FITC and DsRed2, and emissions wave-
lengths were separated by band-pass (505–530 nm) and
long-pass (585 nm) filters, respectively. Framescan rates
varied from 1.9 to 3.9 s with a line average of 2; multi-
tracking (frame-switching) was used for two-color imaging
analysis. The image was deconvolved using Huygens
essential software (Scientific Volume Imaging, Hilversum,
The Netherlands).
Immunoblotting
To detect total cellular expression of nef, the cells were
lysed in triple-detergent lysis buffer [50 mM Tris (pH 8.0),
150 mM NaCl, 0.1% SDS, 100 Ag/ml phenylmethylsul-
fonyl fluoride, 1 mg/ml aprotinin, 1% Nonidet P-40, 0.5%
sodium deoxycholate]. The obtained samples were run on
a 4–12% NuPAGE Bis–Tris gel (Invitrogen) using mor-
pholine ethanesulfonic acid (MES), SDS (sodium dodecyl
sulfate) buffer (1000 mM MES, 1000 mM Tris, 70 mM
SDS, 20 mM EDTA) under reducing conditions, and
transferred to a PVDF (polyvinylidene difluoride) mem-
brane (ATTO, Tokyo, JAPAN). The membrane was incu-
bated with rabbit anti-Nef serum (NIH AIDS Research and
Reference Reagent Program) (Shugars et al., 1993) and
immunoblotting was carried out using horseradish perox-
idase-conjugated goat anti-rabbit IgG (Jackson Immunor-
esearch Lab.) and 3,3V,5,5V-affect tetramethylbenzidine
(TMB) substrate kit for peroxidase (VECTOR lab., Bur-
lingame, CA).
Statistical analysis
Statistical differences between groups were determined
with Student’s t test paired analysis.Acknowledgments
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